TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29442610

Group type: EXPERIMENTAL
Intervention: Randomized Play‐the‐Winner
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Birth‐and‐Death Urn with Immigration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Play‐the‐Winner
Number of subjects: 0

Group type: COMPARATOR
Intervention: Equal allocation design
Number of subjects: 0
Study: 26988767

Group type: EXPERIMENTAL
Intervention: 6 mmol beetroot juice (BR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 6 mmol sodium nitrate (NIT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 12 mmol beetroot juice (BR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 12 mmol sodium nitrate (NIT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 mmol beetroot juice (BR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 mmol sodium nitrate (NIT)
Number of subjects: 12
Study: 24510351

Group type: EXPERIMENTAL
Intervention: Optic flow speed (OS) at levels 0.8, 1.2, and 1.8 m/s with dot density (1, 2, and 3 dots/m²)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Walking parameters and interlimb coordination during navigation
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Three-dimensional kinematic data collection
Number of subjects: 53
Study: 22984007

Group type: EXPERIMENTAL
Intervention: Telemedicine arm (hub telestrokologist interpreting CT scans)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Telephone arm (spoke radiologist interpreting CT scans)
Number of subjects: 54
Study: 20100963

Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 51
Study: 18059577

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.1 g.kg(‐1).d(‐1))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 18
Study: 11158747

Group type: EXPERIMENTAL
Intervention: Amprenavir (1,200 mg twice a day for 4 days, followed by a washout period, then amprenavir plus rifabutin (300 mg QD) for 10 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amprenavir (1,200 mg twice a day for 4 days, followed by a washout period, then amprenavir plus rifampin (600 mg QD) for 4 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amprenavir
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rifabutin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rifampin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amprenavir plus rifabutin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amprenavir plus rifampin
Number of subjects: 24
Study: 9039154

Group type: EXPERIMENTAL
Intervention: Clonidine 0.15 mg + captopril 6.25 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Captopril 6.25 mg + placebo
Number of subjects: 16
Study: 8316771

Group type: COMPARATOR
Intervention: Hydroxychloroquine alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dapsone alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination therapy (Hydroxychloroquine + Dapsone)
Number of subjects: 80
Study: 3526218

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 15
Study: 28923526

Group type: EXPERIMENTAL
Intervention: Nabiximols (Sativex®)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study: 28214093

Group type: EXPERIMENTAL
Intervention: Education for Christian church leaders on scientific, religious, and cultural aspects of male circumcision (1-day seminar and bi-weekly meetings during the campaign)
Number of subjects: 145028

Group type: COMPARATOR
Intervention: Standard outreach activities provided by the Ministry of Health
Number of subjects: 145028
Study: 26196084

Group type: COMPARATOR
Intervention: Osmotic dilators alone
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 400 micrograms buccal misoprostol 3 hours preoperatively
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 200 mg oral mifepristone during dilator placement
Number of subjects: 300
Study: 23781269

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (5 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no acupuncture treatment)
Number of subjects: 30
Study: 19717479

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 232

Group type: COMPARATOR
Intervention: i.v. benzyl penicillin
Number of subjects: 232
Study: 17716735

Group type: EXPERIMENTAL
Intervention: Oral supplementation of vitamin C (180 mg), vitamin E (30 mg), zinc (22.5 mg), copper (1 mg), lutein (10 mg), zeaxanthin (1 mg), and astaxanthin (4 mg) daily for 12 months (T-AMD group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No dietary supplementation (NT-AMD group)
Number of subjects: 27
Study: 17378372

Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study: 14725410

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine, Avaxim 80 paediatric, given as a two-dose schedule with the second dose at 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine, Avaxim 80 paediatric, given as a two-dose schedule with the second dose at 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine, Avaxim 80 paediatric, given as a two-dose schedule with the second dose at 18 months
Number of subjects: 0
Study: 10950003

Group type: EXPERIMENTAL
Intervention: Topical 10 percent phenylephrine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 12
Study: 8972371

Group type: EXPERIMENTAL
Intervention: One intraoperatively adjusted cross suture
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: One unadjusted cross suture
Number of subjects: 75

Group type: COMPARATOR
Intervention: No suture (sutureless)
Number of subjects: 75
Study: 1466529

Group type: EXPERIMENTAL
Intervention: Electrical nerve stimulation (ENS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo ENS
Number of subjects: 64
Study: 29223599

Group type: EXPERIMENTAL
Intervention: varenicline tartrate
Number of subjects: 206

Group type: COMPARATOR
Intervention: bupropion hydrochloride sustained-release
Number of subjects: 206

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: baseline NER (measured by corrugator EMG activity)
Number of subjects: 206
Study: 26797266

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day
Number of subjects: 90
Study: 24796977

Group type: EXPERIMENTAL
Intervention: CHO7% (7% carbohydrate solution)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: lowCHO1.5% (1.5% carbohydrate solution)
Number of subjects: 7

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 7
Study: 22293726

Group type: EXPERIMENTAL
Intervention: Education combined with individual sleep modification training (one‐on‐one group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleep hygiene group education (control group)
Number of subjects: 0
Study: 20177856

Group type: EXPERIMENTAL
Intervention: Intravenous carbohydrate administration (glucose, magnesium, potassium)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Oral carbohydrate administration (specifically composed solution)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Fasting from midnight (control group)
Number of subjects: 221
Study: 19040000

Group type: EXPERIMENTAL
Intervention: Alen + calcium group (n = 74) receiving Alen 10 mg once a day and castrate D 600 0.6 g once a day for 24 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (n = 66) receiving castrate D 600 0.6 g once a day for 24 weeks
Number of subjects: 140
Study: 16330203

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous replacement fluid therapy (FT)
Number of subjects: 30
Study: 14576555

Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.0625% levobupivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1 mug/ml fentanyl
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.0625% levobupivacaine and 1 mug/ml fentanyl
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.0625% levobupivacaine without fentanyl
Number of subjects: 120
Study: 10742638

Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy (BCT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Individual-based treatment (IBT)
Number of subjects: 40
Study: 8629887

Group type: EXPERIMENTAL
Intervention: alpha‐methylparatyrosine
Number of subjects: 19

Group type: COMPARATOR
Intervention: diphenhydramine
Number of subjects: 19
Study: 1602291

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg d-1, Group I, n = 4)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No aspirin (Group II, n = 5)
Number of subjects: 9
Study: 6715692

Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31250776

Group type: EXPERIMENTAL
Intervention: Intravoxel incoherent motion imaging
Number of subjects: 5
Study: 28815684

Group type: EXPERIMENTAL
Intervention: Cognitive psychophysiological (CoPs) intervention for 14 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 64
Study: 27169837

Group type: EXPERIMENTAL
Intervention: 50 mg quercetin‐3‐O‐glucoside
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 mg quercetin‐3‐O‐glucoside
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 200 mg quercetin‐3‐O‐glucoside
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 400 mg quercetin‐3‐O‐glucoside
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0 mg quercetin‐3‐O‐glucoside (control)
Number of subjects: 15
Study: 24280722

Group type: EXPERIMENTAL
Intervention: Sublobar resection
Number of subjects: 347

Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Sublobar resection (for tumors 20 mm or less)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Lobectomy (for tumors 20 mm or less)
Number of subjects: 347
Study: 21792687

Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency tonsillotomy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser tonsillotomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both methods (radiofrequency and laser tonsillotomy)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Radiofrequency tonsillotomy
Number of subjects: 26
Study: 21049059

Group type: EXPERIMENTAL
Intervention: Paromomycin (PM) at 15 mg/kg/day for 21 days
Number of subjects: 135

Group type: COMPARATOR
Intervention: Sodium stibogluconate (SSG) at 20 mg/kg/day for 30 days
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Combination of PM and SSG
Number of subjects: 135
Study: 18990781

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Number of subjects: 85000

Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 85000
Study: 15756061

Group type: EXPERIMENTAL
Intervention: Thick loop TURP
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard loop TURP
Number of subjects: 103
Study: 11788911

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin, fluorouracil (5‐FU), l‐leucovorin and interferon alpha2b (PFL‐IFN)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy with 5‐FU, hydroxyurea and radiation (FHX)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Overall survival and progression-free survival
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Toxicity assessment
Number of subjects: 26
Study: 10438259

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1200 mg per day)
Number of subjects: 2531

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2531
Study: 7586435

Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood cardioplegia
Number of subjects: 720
Study: 2147914

Group type: EXPERIMENTAL
Intervention: 250 mg ticlopidine twice daily
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: 500 mg aspirin every third day plus 75 mg dipyridamole three times daily
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: 300 mg xanthinol nicotinate three times daily
Number of subjects: 296
Study: 6996932

Group type: EXPERIMENTAL
Intervention: 500 mg dipyrone
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: 500 mg aspirin
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 31116404

Group type: EXPERIMENTAL
Intervention: Children's Healthy Living (CHL) intervention
Number of subjects: 0
Study: 31083151

Group type: EXPERIMENTAL
Intervention: Guardix-SG
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control
Number of subjects: 214
Study: 29036255

Group type: EXPERIMENTAL
Intervention: tavaborole 5% solution
Number of subjects: 84

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 84
Study: 26520398

Group type: EXPERIMENTAL
Intervention: RT combined with NMES (RT + ES)
Number of subjects: 39

Group type: COMPARATOR
Intervention: RT with sham stimulation (RT + Sham)
Number of subjects: 39
Study: 23410889

Group type: EXPERIMENTAL
Intervention: MVA85A vaccine
Number of subjects: 2797

Group type: COMPARATOR
Intervention: Candin control
Number of subjects: 2797
Study: 22832391

Group type: EXPERIMENTAL
Intervention: 40 UI of vasopressin intranasally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo intranasally
Number of subjects: 20
Study: 19332190

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration in patients with STEMI
Number of subjects: 11177

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration in patients with non-STEMI
Number of subjects: 11177

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration in patients with unstable angina
Number of subjects: 11177

Group type: EXPERIMENTAL
Intervention: Clopidogrel use in patients with non-ST elevation ACS with positive cardiac biomarkers
Number of subjects: 11177

Group type: EXPERIMENTAL
Intervention: Clopidogrel use in patients with non-ST elevation ACS without positive cardiac biomarkers
Number of subjects: 11177

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration in patients <65 years old receiving fibrinolytic therapy for STEMI
Number of subjects: 11177

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration in patients 65 to 74 years old receiving fibrinolytic therapy for STEMI
Number of subjects: 11177

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration in patients >75 years old receiving fibrinolytic therapy for STEMI
Number of subjects: 11177
Study: 17179870

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention consisting of one in-person counseling session followed by two MI telephone calls over 6 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group received two telephone calls without MI content
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 15785163

Group type: EXPERIMENTAL
Intervention: Trandolapril (angiotensin-converting enzyme inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contemporary therapeutic regimen (without trandolapril)
Number of subjects: 0
Study: 15259398

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex (2 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cholinesterase inhibitor (THA)
Number of subjects: 13
Study: 9440036

Group type: EXPERIMENTAL
Intervention: Adverse neural tension assessed using the slump test
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (injury-free matched control group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hamstring flexibility measured using the active knee extension in lying test
Number of subjects: 14
Study: 7605022

Group type: EXPERIMENTAL
Intervention: Propofol (target concentrations of 2, 4, or 6 micrograms/ml) with alfentanil (initial target concentration 50 ng/ml)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alfentanil (plasma concentrations increasing from 10 to 150 ng/ml)
Number of subjects: 21
Study: 2398251

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 21
Study: 377119

Group type: EXPERIMENTAL
Intervention: Anginin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31517811

Group type: EXPERIMENTAL
Intervention: Rational Emotive Occupational Health Coaching (REOHC) for 12 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 63
Study: 28428110

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 3140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3140

Group type: EXPERIMENTAL
Intervention: Peak flow categorized as 10 to 14.9 ml/s
Number of subjects: 3140

Group type: EXPERIMENTAL
Intervention: Peak flow categorized as less than 10 ml/s
Number of subjects: 3140

Group type: EXPERIMENTAL
Intervention: Peak flow categorized as 15 or greater ml/s
Number of subjects: 3140

Group type: EXPERIMENTAL
Intervention: Peak flow categorized as 10 to 14.9 ml/s (multivariable analysis)
Number of subjects: 3140
Study: 26168262

Group type: EXPERIMENTAL
Intervention: Family Focused Therapy for Clinical High‐Risk (FFT‐CHR), an 18-session intervention consisting of psychoeducation and training in communication and problem solving.
Number of subjects: 90

Group type: COMPARATOR
Intervention: 3-session family psychoeducational intervention (Control group).
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both treatment groups (FFT-CHR and control).
Number of subjects: 90
Study: 23904409

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Spironolactone with prednisolone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Spironolactone (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined glucocorticoid receptor/mineralocorticoid receptor stimulation with prednisolone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Spironolactone with prednisolone (control group)
Number of subjects: 24
Study: 21734467

Group type: EXPERIMENTAL
Intervention: rMenB
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: rMenB+OMVNW
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (licensed quadrivalent meningococcal polysaccharide vaccine and hepatitis B vaccine)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: rMenB and rMenB+OMVNW
Number of subjects: 104
Study: 19388866

Group type: EXPERIMENTAL
Intervention: guaraná 75 mg daily p.o.
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 16626411

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Fail-first algorithm on conventional antipsychotics (CON)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Risperidone (RIS)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment requiring switching
Number of subjects: 664
Study: 14697107

Group type: EXPERIMENTAL
Intervention: Intervention involving interviews with surrogates and decisionally capable older children regarding information adequacy, understanding, communication, and perceived decisional conflicts.
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Intervention involving tailored follow‐up recommendations based on findings relayed to the clinical team.
Number of subjects: 127
Study: 10765588

Group type: EXPERIMENTAL
Intervention: Global recruitment strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three methods of recruitment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobilization of community resources
Number of subjects: 0
Study: 8936399

Group type: EXPERIMENTAL
Intervention: 150 mg of caffeine in coffee
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: shorter than 15 min nap
Number of subjects: 10

Group type: COMPARATOR
Intervention: coffee placebo
Number of subjects: 10
Study: 1984696

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 18
Study: 6854139

Group type: EXPERIMENTAL
Intervention: DMSO (30 ml, 70% solution)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sulindac (400 mg, orally)
Number of subjects: 8
Study: 31820304

Group type: EXPERIMENTAL
Intervention: 10-mg orodispersible tablet (DT1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 10-mg oral solution (SOL)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 10-mg orodispersible tablet without water (DT2dry)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 10-mg orodispersible tablet with water (DT2water, reference formulation)
Number of subjects: 23
Study: 31663285

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg once daily for 16 days)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Rivaroxaban (10 mg once daily for 16 days)
Number of subjects: 390
Study: 29023203

Group type: EXPERIMENTAL
Intervention: Media portrayal where mental illness was stigmatized
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Media portrayal where mental illness was trivialized
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Specific examples of different mental illness portrayals
Number of subjects: 316
Study: 26791022

Group type: EXPERIMENTAL
Intervention: exercise + smoking cessation maintenance
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: exercise maintenance + contact control
Number of subjects: 413

Group type: COMPARATOR
Intervention: smoking cessation maintenance + contact control
Number of subjects: 413

Group type: COMPARATOR
Intervention: contact control
Number of subjects: 413
Study: 26197999

Group type: EXPERIMENTAL
Intervention: 2.5 mg elobixibat
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 5 mg elobixibat
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 15 mg elobixibat
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 mg elobixibat
Number of subjects: 36